[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thymic-epithelial-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thymic-epithelial-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,76,109,134,161,186,210,241,263,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100447307","phase-2-pt-112-in-subjects-with-thymoma-and-thymic-carcinoma-100447307",false,"NCT05104736","PT-112 in Subjects With Thymoma and Thymic Carcinoma","A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma","* INCLUSION CRITERIA:\n* Participants must have histologically confirmed thymoma or thymic carcinoma.\n* Participants should have received at least one prior line of platinum-based chemotherapy. For participants who have refused cytotoxic chemotherapy, a rationale for refusal to receive standard first-line therapy will be captured in the case report form and the medical record. Progressive disease must be documented prior to study entry and participants must have advanced, unresectable disease that is not amenable to surgical resection.\n* Disease must be measurable with at least 1 unidimensional measurable lesion by RECIST 1.1.\n* Participants must be aged \\>=18 years.\n* ECOG performance status \\\u003C=1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * absolute neutrophil count \\>= 1,500\u002Fmm3 OR \\>= 1.5 x 10(9)\u002FL\n  * platelets \\>=100,000\u002Fmm3 OR (Bullet) 100 x 10(9)\u002FL\n  * hemoglobin \\>= 9g\u002FdL (may have been transfused, at least 7 days prior)\n  * total bilirubin \\\u003C= 1.5 x the upper limit of normal range (ULN)\n  * AST(SGOT)\u002FALT(SGPT) \\\u003C= 2.5 x ULN OR \\\u003C= 5 x ULN for participants with documented metastatic disease to the liver\n  * creatinine \\\u003C= 1.5x ULN OR:\n  * creatinine clearance \\>= 60 mL\u002Fmin\u002F1.73 m2 calculated by calculated using eGRF in the clinical lab\n* Negative serum or urine pregnancy test at screening for individuals of childbearing potential (IOCBP). NOTE: IOCBP is defined as any individual who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal. Absence of pregnancy must be demonstrated unless there is proven menopause (age \\>= 50 years and last menarche \\>= 3 years, or documented menopausal sex hormone profile, or surgical castration) at screening.\n* Participants must not become pregnant or start breast feeding during the study. Breastfeeding should be discontinued if the mother is treated with PT-112.\n* Individuals of child-bearing potential and those that can father children with a sexual partner of childbearing potential must use medically effective contraception during the study and for 6 months after the last dose of study medication.\n* Participants with previously treated brain or CNS metastases are eligible provided that the participant has recovered from any acute side effects of radiotherapy and does not require treatment with steroids, and any whole brain radiation therapy was completed at least 2 weeks prior to initiation of study therapy.\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to PT-112. Since there is no definitive list of compounds of similar chemical or biologic composition to PT-112, the principal investigator if in doubt, will report known allergies to the pharmacist to make a determination as to whether it is safe to enroll a participant.\n* Concurrent treatment with a non-permitted drug.\n* Concurrent anticancer treatment within 14 days before initiation of study therapy (includes radiotherapy; however, palliative bone-directed radiotherapy is permitted).\n* Major surgery within 14 days before enrollment (excluding prior diagnostic biopsy).\n* Concurrent systemic therapy with immunosuppressive agents within 14 days (or 5 half-lives of a drug, whichever is shorter) before initiation of study therapy.\n* Use of hormonal agents for anti-cancer therapy within 14 days before initiation of study therapy; or use of any investigational drug within 14 days before initiation of study therapy.\n* History of previous malignant disease within the last 2 years with the following exceptions: basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast, papillary or follicular thyroid carcinoma, and non-muscle invasive bladder cancer.\n* Active infection requiring systemic therapy or significant acute or chronic infections including, among others:\n\n  * Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).\n  * Known history of testing positive for HIV or known acquired immunodeficiency syndrome with a detectable viral load. However, participants with HIV who have an undetectable viral load and are on stable doses of Highly Active Antiretroviral Therapy (HAART) can be screened for the study.\n* Persisting toxicity related to prior therapy (NCI CTCAE v. 5 Grade \\> 1) with the exception of, alopecia, sensory neuropathy Grade \\\u003C= 2 and hearing loss Grade \\\u003C=2.\n* Known alcohol or drug abuse.\n* Uncontrolled intercurrent illness including, but not limited to the following:\n\n  * Cardiovascular: SYMPTOMATIC congestive heart failure, unstable angina pectoris or cardiac arrhythmia, either active or within the past 6 months\n  * Respiratory: Pneumonitis or Idiopathic pulmonary fibrosis (not radiation-associated fibrosis), either active or within the past 6 months\n  * Gastrointestinal: Immune colitis or inflammatory bowel disease, either active or within the past 6 months\n  * Hematological: Bleeding diathesis or major bleeding events, either active or within the past 6 months\n  * Other: psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, including active suicidal ideation or behavior, either active or within the past 12 months\n* Administration of live vaccines within 4 weeks prior to treatment. COVID-19 vaccines are permitted at screening.","ALL","18 Years","120 Years",{"count":20,"type":21},53,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nThere are no approved drugs to treat recurrent thymoma and thymic carcinoma. New therapies are needed for people with these cancers. Researchers want to see if the drug PT-112 can help. PT-112 kills cancer cells. It also helps the body s immune system fight cancer.\n\nObjective:\n\nTo see if the study drug PT-112 can cause tumors to shrink.\n\nEligibility:\n\nPeople ages 18 and older who have thymoma or thymic cancer and whose disease returned or progressed after treatment with at least one platinum-containing chemotherapy, or who have refused standard treatment.\n\nDesign:\n\nParticipants will be screened with:\n\nReview of medical history and medications\n\nPhysical exam\n\nBlood and urine tests\n\nCT or MRI scans of parts of the body, including the brain\n\nParticipants will get PT-112 in 28-day cycles, on days 1 and 15 of of the first cycle and on day 1 of each cycle after that. They will get the drug by infusion through a catheter. The catheter is a small plastic tube put into a vein. On days they receive the drug, participants will have physical exams and blood and urine tests. They will have an ECG to test heart function on day 1 of each cycle.\n\nParticipants will have scans every 8 weeks.\n\nParticipants may choose to have tumor biopsies on day 1 of cycles 1 and 3. Biopsies may be guided by an ultrasound or CT scan.\n\nParticipants will continue treatment as long as they can handle the side effects and their disease does not get worse, for up to 8 years.\n\nParticipants will have follow-up visits 2 weeks and 4 weeks after they stop therapy. Then the study team will check on participants every 3 months until 8 years after the participant joined the study.",[27,28,29],"Thymic Epithelial Tumor","Recurrent Thymoma","Thymic Cancer",[31,32,33,34,35],"metallo-pyrophosphate","immunogenic cell death","osteotropism","damage-associated molecular patterns","Peripheral Neuropathy","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":40},"2022-04-06",{"date":44,"type":21},"2028-06-30",{"name":46,"class":47},"National Cancer Institute (NCI)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100622401","intrathoracic-chemotherapy-for-tets-with-pleural-spread-or-recurrence-choice-2-100622401","NCT07383142","Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence (CHOICE-2)","Surgery Combined With Hyperthermic Intrathoracic Chemotherapy Versus Surgery Alone for Pleural Dissemination or Pleural Recurrence of Thymic Epithelial Tumors: A Prospective, Multicenter, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age range: 18-75 years old; Expected survival time \\> 12 months; Preoperative imaging (CT, MRI, or PET-CT) clinically diagnosed as TETs\n2. Patients with de novo stage IVa thymoma (DNT) diagnosed by the multidisciplinary team (MDT) are eligible if deemed suitable for surgery under any of the following conditions: (1) candidates for primary surgery without contraindications; (2) candidates for staged surgery who have completed phase I surgery and are reassessed by the MDT as eligible for phase II surgery 3 months postoperatively; or (3) patients initially requiring induction therapy, provided the diagnosis is pathologically confirmed by biopsy, induction therapy is administered according to TET guidelines, imaging and laboratory evaluations are performed 4-6 weeks after completion of therapy, and the MDT confirms the absence of surgical contraindications upon re-evaluation.\n3. For patients with thymoma with pleural recurrence (TPR), the initial surgery must have achieved complete resection without evidence of pleural dissemination or intraoperative tumor rupture, and the interval between the first surgery and the development of pleural metastasis must be longer than 6 months.\n4. According to the definition of T1-3NxM1a stage, no intrapericardial dissemination, no intrapulmonary parenchymal metastatic nodules, no distant organ metastasis (M1b)\n5. During the operation, the pleural nodules were removed. The frozen section pathology during the operation confirmed that the pleural nodules were TETs pleural metastatic nodules.\n6. No history of other malignant tumors, except for patients who had prior malignancies treated with curative surgery, were confirmed to have pathologic stage I disease requiring no adjuvant therapy (e.g., resected pulmonary ground-glass opacity or papillary thyroid carcinoma) and have remained free of recurrence for more than 5 years.\n7. ASA stage I\u002FII\n8. Be able to understand the situation of this study and sign the Informed Consent form.\n\nExclusion Criteria:\n\n1. Preoperative imaging examinations such as CT, MRI or PET-CT, or intraoperative exploration revealed that the tumor involved the ascending aorta, aortic arch, descending aorta, intrapericardial pulmonary vessels, heart, trachea or esophagus (T4), or had dissemination within the pericardium (M1a) or hematogenous metastasis (M1b stage);\n2. Within 4-6 weeks after completion of induction therapy (chemotherapy, radiotherapy, immunotherapy, or targeted therapy), imaging studies (CT or PET-CT) and laboratory evaluations (complete blood count, liver and renal function, cardiac biomarkers, and thyroid function) were performed by the mediastinal MDT to assess surgical eligibility; patient found to have surgical contraindications and deemed unsuitable for surgery or HITOC were excluded;\n3. The diagnosis was confirmed by biopsy or puncture as a non-TETs type (such as lymphoma, neurogenic tumor, germ cell tumor, thymic lipoma, thymic sarcoma or neuroendocrine tumor);\n4. The patient had a history of multiple surgeries in the past (≥2), the initial surgery of TPR was palliative resection, and pleural dissemination was a iatrogenic implantation site; or the patient received a radiotherapy dose greater than 60 Gy before enrollment;\n5. Had other active malignant tumors, or had received anti-tumor treatment (chemotherapy, radiotherapy, immunotherapy, small molecule targeted therapy or other anti-tumor biological agents) for other malignant tumors in the past;\n6. The patient had myasthenia gravis in an unstable state or during an acute exacerbation;\n7. Had the following major cardiovascular disease histories: congestive heart failure, poorly controlled angina pectoris, transmural myocardial infarction, high-risk arrhythmia, significant valvular disease or poorly controlled hypertension, cardiovascular compensatory dysfunction;\n8. The patient had a weight loss of more than 5 kg within the past one month; severe uncontrolled systemic systemic diseases, such as active infection or poorly controlled diabetes; patients with bleeding disorders and those with bleeding tendencies; patients with abnormal coagulation function, with bleeding tendencies or undergoing thrombolysis or anticoagulation treatment; patients with grade II-IV bone marrow suppression;\n9. The patient had a history of thoracic surgery due to tuberculous pleurisy or mesothelioma, and the contralateral lung atrophy involved one or more lung lobes or more than one lung lobe;\n10. The patient had an allergy history to cisplatin or doxorubicin drugs;\n11. Had a history of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation); Had a history of mental disorders, neurological diseases or other central nervous system diseases affecting compliance;\n12. The patient was in the acute inflammatory stage due to bacterial, viral or other pathogenic microorganism infection; Had active infection of immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or known HIV seropositivity;\n13. Pregnant or lactating women, and fertile men and women who were unwilling to use adequate contraceptive measures during treatment;\n14. The patient had received grade IV surgical treatment within 2 months or was in a recovery state due to other diseases or was in the intervention period of other research projects.","75 Years",{"count":58,"type":21},202,[60],"NA","Hyperthermic intrathoracic chemotherapy (HITOC) offers a strategy to eliminate microscopic residual disease after surgical resection. Especially it is investigated to improve long-term survival in thymic epithelial tumors with pleural dissemination or recurrence. A prospective, multicenter, randomized phase III clinical trial (CHOICE-2) is conducted to compare the efficacy and safety of surgery combined with HITOC versus surgery alone. The HITOC regimen involves intrathoracic perfusion with doxorubicin on postoperative day 1 and cisplatin on postoperative day 2.",[27],[64],"Hyperthermic Intrathoracic Chemotherapy","NOT_YET_RECRUITING","2026-02-04",{"date":68,"type":40},"2026-02-06",{"date":70,"type":21},"2026-02-01",{"date":72,"type":21},"2032-02-01",{"name":74,"class":75},"Shanghai Zhongshan Hospital","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100618165","electrocautery-resection-combined-with-hithoc-for-thymic-epithelial-tumors-with-pleural-metastasis-100618165","NCT07328074","Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis","Prospective Cohort Study of Electrocautery Resection Combined With Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors With Pleural Metastasis","Inclusion Criteria:\n\n* Pathologically confirmed thymic epithelial tumor (TET)\n* Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team\n* Age ≥16 years and ≤80 years\n* American Society of Anesthesiologists (ASA) physical status classification I-II\n* Normal major organ function\n* No history of other malignancies\n* Prior chemotherapy completed \\>4 weeks, radiotherapy \\>6 weeks, immunotherapy \\>6 weeks before enrollment\n* No allergy to cisplatin or doxorubicin\n* Able to understand the study content and provide informed consent\n\nExclusion Criteria:\n\n* Evidence of extrathoracic metastasis on imaging or pathological examination\n* Myasthenia gravis in unstable phase or acute exacerbation\n* Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic\u002Fanticoagulation therapy\n* Positive serum pregnancy test or lactation (females)\n* History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)\n* History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease\n* Currently participating in other clinical trials","16 Years","80 Years",{"count":86,"type":21},70,"36 Months","OBSERVATIONAL","The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to:\n\n* Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors\n* Assess the rates of grade ≥3 treatment-related adverse events\n* Examine how this treatment affects patients' quality of life\n\nParticipants will:\n\n* Undergo extended thymectomy with electrocautery resection of pleural metastases\n* Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart\n* Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals\n* Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression",[27,91,92,93,94],"Thymoma","Thymic Carcinoma","Pleural Metastasis","Pleural Recurrence",[64,96,97,98,99],"HITHOC","Electrocautery","Cisplatin","Doxorubicin","2026-02-02",{"date":102,"type":40},"2026-02-05",{"date":104,"type":21},"2026-02",{"date":106,"type":21},"2031-02",{"name":108,"class":75},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":48},"100540062","phase-2-clinical-study-of-postoperative-carbon-ion-radiotherapy-for-thymus-tumor-with-residual-tumor-100540062","NCT06311955","Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor","Prospective Phase II Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymic Epithelial Malignant Tumor Received R2 Resection","Inclusion Criteria:\n\n* Patients with stage II-IV (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiotherapy who had undergone radical surgery (R2 resection, visible residual tumor) and had a definite pathological diagnosis.\n* Sign informed consent.\n* Between the ages of 18 and 70.\n* ECOG general status score of 0-2.\n* The expected survival is at least 6 months.\n* Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109\u002FL, platelet count ≥80 x 109\u002FL, hemoglobin ≥9 g\u002FdL 2). Lung function: FEV1\\>25%, DLCO\\>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin \\\u003C1.5 times the upper limit of normal value, and AST, ALT\\\u003C2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml \u002Fmin, and urinary protein \\\u003C2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.\n\nExclusion Criteria:\n\n* Complicated with other malignant tumors that have not been controlled.\n* Have large quantity of pleural or pericardial effusion.\n* Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.\n* Chest radiation therapy or radioactive particle implantation history.\n* Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.\n* Pregnancy (confirmed by serum or urine β-HCG test) or lactation period.\n* HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.\n* A history of mental illness may hinder the completion of treatment.\n* With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.\n* Other circumstances that the physician considers inappropriate to participate in clinical study.","70 Years",{"count":118,"type":21},48,[24],"To observe the efficacy and toxicities of heavy ion radiation therapy for locally advanced or advanced primary thymic epithelial malignant tumor received R2 resection. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.",[27,122,123,124],"Radiotherapy Side Effect","Carbon Ion Radiotheray","Heavy Ion Radiotherapy","2025-06-10",{"date":127,"type":40},"2025-06-13",{"date":129,"type":21},"2025-07-01",{"date":131,"type":21},"2029-02-28",{"name":133,"class":75},"Jian Chen",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":48},"100490578","molecular-analysis-and-treatment-options-of-thymic-malignancies-100490578","NCT05667948","Molecular Analysis and Treatment Options of Thymic Malignancies","Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors","Inclusion Criteria:\n\n* Histologically proven diagnosis of thymic malignancies\n* 18 years of age or older\n* Ability to understand and the willingness to sign a written informed consent document",{"count":142,"type":21},500,"Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.\n\nIn summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.",[27,92,29],[146,147,148,149,150,151],"thymic malignancy","thymoma","chemotherapy","targeted therapy","immunotherapy","molecular landscape","2025-05-20",{"date":154,"type":40},"2025-05-22",{"date":156,"type":40},"2016-01-01",{"date":158,"type":21},"2026-12-31",{"name":160,"class":75},"Shanghai Chest Hospital",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":48},"100569270","hypofractionated-radiotherapy-for-thymic-epithelial-tumors-100569270","NCT06692062","Hypofractionated Radiotherapy for Thymic Epithelial Tumors","A Prospective Study of Hypofractionated Radiotherapy for Thymic Epithelial Tumors","Inclusion Criteria:\n\n1. Patients must provide written informed consent.\n2. 18 years old ≤ age \\\u003C75 years old.\n3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data.\n4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ\n5. ECOG performance status 0-2.\n6. Expected survival time \\> 1 year.\n7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.\n8. Patients who are not lactating.\n9. Sufficient bone marrow reserve and good function of important organs.\n\nExclusion Criteria:\n\n1. patients with prior thoracic radiotherapy;\n2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;\n3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care\n4. Patients with other malignant tumors that are not under stable control;\n5. Known history of mental illness, substance abuse, alcohol or drug abuse.\n6. Other conditions deemed unsuitable for enrollment by the attending physician.",{"count":169,"type":21},100,[60],"The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are:\n\n* Does Hypofractionated radiotherapy provide better results?\n* Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery.\n\nParticipants will:\n\n* Receive hypofractionated radiotherapy or conventional radiotherapy\n* Visit the hospital regularly once every 12 weeks for checkups and tests",[173,91,29,27],"Thymoma and Thymic Carcinoma",[147,175,176],"hypofractionated radiotherapy","thymic carcinoma","2024-11-15",{"date":179,"type":40},"2024-11-18",{"date":181,"type":40},"2024-10-01",{"date":183,"type":21},"2027-11-01",{"name":185,"class":75},"Rongrong Zhou",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100566411","phase-2-ratt-vs-vatt-for-early-stage-tets-100566411","NCT06654830","RATT Vs. VATT for Early-stage TETs","Robotic-assisted Versus Video-assisted Thoracoscopic Thymectomy for Thymic Epithelial Tumor in Stage I-II: a Prospective, Multi-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* Thymoma was diagnosed by chest enhanced CT or MRI (clinical stage: Masaoka Koga I-II) with AJCC\u002FUICC TNM grade system (9th edition).\n\nThe patients whose tumor diameter was not larger than 8 cm; The patients with the estimated survival time should be over 12 months; ASA grade：1-2; The patients should have no functional disorders in main organs; The patients should be able to understand our research and sign the informed consent.\n\nExclusion Criteria:\n\n* Imaging examination showed that the tumor had invasion of surrounding organs, pleural or pericardial dissemination, lymphatic or hematogenous metastasis; Patients with myasthenia gravis; Patients had undergone a sternotomy; The patients have proved history of congestive heart failure, angina without good control with medicine; ECG-proved penetrating myocardial infarction; hypertension with bad control; valvulopathy with clinical significance; arrhythmia with high risk and out of control; The patients have severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under treatment of thrombolysis or anticoagulant therapy; Female who is positive for serum pregnancy test or during lactation period; The patients have history of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation; The patients have history of peripheral nerve system disorders, obvious mental disorders or central nerve system disorders; The patients attend other clinical trials.",{"count":169,"type":21},[24],"This study is a prospective, multicenter, phase II randomized controlled trial. We plan to screen 100 eligible thymoma patients for robotic-assisted thoracoscopic thymectomy (RATT) or video-assisted thoracoscopic thymectomy (VATT) at three medical centers in China. The trial was aimed to compare the perioperative outcomes between the two approaches.",[27],[198,199,200,201],"thymic epithelial tumor","robot-assisted","video-assisted","thoracoscopic thymectomy","2024-10-26",{"date":204,"type":40},"2024-10-30",{"date":206,"type":21},"2024-11-01",{"date":208,"type":21},"2027-11-30",{"name":74,"class":75},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":218,"targetDuration":220,"studyType":88,"phases":4,"briefSummary":221,"conditions":222,"keywords":229,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":48},"100548500","establishing-prospective-mediastinal-tumor-database-of-pumch-100548500","NCT06421805","Establishing Prospective Mediastinal Tumor Database of PUMCH","A Single-center, Prospective, and Observational Study on Population Characteristics, Pathological Features, and Prognostic Factors of Patients With Mediastinal Tumor: Establishing Mediastinal Tumor Database of PUMCH.","MTDPUMCH","Inclusion Criteria:\n\n1. Clinical or pathological diagnosis of mediastinal tumors;\n2. Written consent is able to obtained.\n\nExclusion Criteria:\n\n1\\. Incomplete clinicopathological information.",{"count":219,"type":21},2000,"20 Years","This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors. Clinical information will be structured and processed, and it is recommended to establish a mediastinal tumors database at Peking Union Medical College Hospital. The goal is to provide support for the quality of diagnosis and treatment, clinical protocols, and medical decision-making related to mediastinal tumors.",[27,223,224,225,226,227,228],"Teratoma","Thymic Cyst","Retrosternal Goitre","Germ Cell Tumor","Lymphoma","Schwannoma",[230,231,198],"mediastinal tumors","database","2024-05-14",{"date":234,"type":40},"2024-05-20",{"date":236,"type":40},"2012-01-01",{"date":238,"type":21},"2045-12-30",{"name":240,"class":75},"Peking Union Medical College Hospital",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":48},"100531471","phase-2-rivoceranib-in-patients-with-metastatic-thymic-epithelial-tumor-100531471","NCT06200233","Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor","A Phase II, Open-label, Single-arm, Multi-center Clinical Trial of Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor","Inclusion Criteria:\n\n1. 19 years of age or older at the time of signing informed consent\n2. Subjects with histologically confirmed metastatic thymic epithelial tumor\n3. Have at least one measurable target lesion for evaluation according to RECIST v1.1 criteria\n4. Patients who are not candidates for surgery and require consolidation chemotherapy\n5. Radiologic progression of disease after first-line standard therapy\n6. ECOG performance status of 0 or 1\n7. Life expectancy greater than 3 months\n8. Patients with adequate bone marrow and organ function \\[Bone marrow function\\]\n\n   * Neutrophils (ANC) \\> 1,500\u002Fmm3\n   * Platelets \\> 100,000\u002Fmm3\n   * Hemoglobin \\> 9 g\u002FdL \\[Liver function\\]\n   * Total bilirubin ≤ 1.5 x upper limit of normal (if liver metastases are present, up to 3 x upper limit of normal is allowed)\n   * AST, ALT ≤ 3 x upper limit of normal (if liver metastases are present, up to 5 x upper limit of normal is allowed) \\[Renal function\\]\n   * Creatinine clearance \\> 50 mL\u002Fmin (Cockcroft-Gault equation)\n9. Subjects who have voluntarily decided to participate in this study and have given written informed consent and are able to participate in all periods of the study.\n\nExclusion Criteria:\n\n1. Patients with more than 22 concurrent tumors and\u002For other active malignancies requiring systemic treatment within the last 22 years at the time of the first dose of investigational drug (however, patients may participate in the study if the principal investigator determines that the previous malignancy has been treated and no further treatment is required).\n2. Patients treated with a previous anti-angiogenic agent (ex. Sunitinib, bevacizumab etc)\n3. Patients with difficult to control central nervous system metastases\n4. Those with spinal cord compression, leptomeningeal carcinomatosis\n5. Patients with uncontrolled systemic disease, including uncontrolled hypertension, active bleeding, or active infection.\n\n   However, individuals with the following hepatitis B\u002FC infections may be enrolled\n   * Hepatitis B surface antigen (HBsAg) positive, with an ALT in the normal range and HBV DNA \\\u003C2,000 IU\u002Fml, and taking antiviral therapy to prevent hepatitis reactivation may be enrolled.\n   * HBs Ag negative, hepatitis B core antibody (IgG anti-HBc) positive, and HBV DNA below the lower limit of quantification may be enrolled.\n   * Anti-HCV Ab positive individuals can be enrolled if HCV RNA is the lower limit of quantification.\n6. Unresolved toxicities from prior therapy greater than or equal to grade 1 based on CTCAE version 5.0.\n7. Received extensive radiotherapy within the last 2 weeks, or received localized radiotherapy or gamma knife surgery with a limited scope of radiotherapy for palliative purposes within the last 1 week.\n8. Unable to swallow investigational medication due to intractable nausea and vomiting or chronic gastrointestinal disease.\n9. Participation in another interventional clinical trial within 30 days of screening\n10. Pregnant or lactating women\n11. Unwilling to agree to use a medically acceptable method of contraception from the first dose of investigational drug until 1 month after the last dose.\n\n    * Female patients of childbearing potential who are sexually active and their partners must agree to use adequate medically acceptable contraception for the duration of the study and for 1 month after the last dose.\n    * Male patients who have not undergone a vasectomy must agree to use adequate contraception and are prohibited from providing sperm until 1 month after the last dose of study medication.\n\n      * Adequate contraception includes: hormonal contraceptives (subcutaneous fat, injections, oral contraceptives, etc.), intrauterine devices (IUD, intrauterine device or IUS, intrauterine system), sterilization of you or your partner (vasectomy, tubal ligation, etc.).\n12. Failure to provide 20 unstained slides (if additional biopsies are not available from the patient, participation in the study may be possible after discussion with the study coordinator).\n13. Those who are inappropriate to participate in the study for other reasons (e.g., ethically or because it may affect the outcome of the study) as judged by the principal investigator.","19 Years",{"count":250,"type":21},40,[24],"PURPOSE: To evaluate the efficacy and safety of Rivoceranib in patients with metastatic thymic epithelial tumors who developed resistance on first-line therapy.\n\nStudy Design: Patients with histologically confirmed metastatic thymic epithelial tumors who meet the inclusion\u002Fexclusion criteria will be enrolled in this study. In Stage 1, 18 subjects will be enrolled to receive study medication. If a tumor response is observed in at least 5 of these subjects, the study will proceed to Stage 2 to enroll the remaining subjects, or the study will be stopped early due to lack of clinical benefit of the investigational product. The trial will be considered clinically valid if a response is observed in 11 or more subjects out of a total of 33 subjects. Investigational product(Rivoceraniv 700 mg) will be administered until disease progression, development of intolerable adverse events, death, withdrawal of consent by the subject, or when, in the opinion of the principal investigator, it is inappropriate or impossible to continue the study. Imaging studies (CT or MRI) will be performed every 8 weeks (+,- 1 week) for C1D1 through 12 months and every 12 weeks (+,- 1 week) after 12 months, and the results will be used to assess tumor response according to RECIST v1.1 criteria. Safety will be assessed at C1D1, C1D7, and each scheduled visit thereafter.",[27],"2024-04-08",{"date":256,"type":40},"2024-04-09",{"date":258,"type":21},"2024-05-01",{"date":260,"type":21},"2026-12-01",{"name":262,"class":75},"Samsung Medical Center",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":48},"100539292","artificial-intelligence-prediction-tool-in-thymic-epithelial-tumors-100539292","NCT06301945","Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors","Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors","INTHYM","Inclusion Criteria:\n\nParticipants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:\n\n* Thymoma A\n* Thymoma AB\n* Thymoma B1\n* Thymoma B2\n* Thymoma B3\n* Thymic Carcinoma\n\nInclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.\n\nRecurrence Criteria:\n\nParticipants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.",{"count":272,"type":21},1020,"Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and\u002For more aggressive subtypes, defined by the WHO histopathological classification.\n\nIn this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.\n\nThe investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.\n\nIn this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.\n\nThe ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.",[27,92,91,173],[276,277],"Artificial Intelligence","Digital pathology","2024-03-26",{"date":280,"type":40},"2024-03-27",{"date":282,"type":40},"2023-08-01",{"date":284,"type":21},"2027-08-01",{"name":286,"class":75},"Erasmus Medical Center",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":305,"locationsCount":48},"100402624","influence-of-radiotherapy-and-chemotherapy-in-the-value-of-peripheral-blood-lymphocyte-subsets-among-thoracic-cancer-100402624","NCT04522687","Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer","Observation of the Impact of Radiotherapy With or Without Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets for Patients With Thoracic Cancer","Inclusion Criteria:\n\nAge at least 18 years. ECOG PS 0-1. Pathologically confirmed NSCLC, esophageal squamous cell carcinoma or thymic epithelial tumor.\n\nLife expectancy of more than 3 months. Patients with no indications for palliative radiotherapy in the opinion of the investigator.\n\nPatients with a prior history of surgery are eligible if they have recovered adequately from the toxicity and\u002For complications of surgery.\n\nSigned informed consent for the use of fresh tumor biopsies before and during the treatment.\n\nWomen of childbearing age and men must agree to use effective contraception during the trial.\n\nAdequate organ function within 1 week prior to the enrollment：\n\n1. Adequate bone marrow function: hemoglobin ≥80g\u002FL, white blood cell (WBC) count ≥ 4.0 \\* 10 \\^ 9\u002FL or neutrophil count ≥ 1.5 \\* 10 \\^ 9\u002FL, and platelet count ≥ 100 \\* 10 \\^ 9\u002FL;\n2. Adequate hepatic function: total bilirubin \\\u003C 1.5 x upper limit of normal (ULN). Note: If total bilirubin is \\> 1.5 x ULN, direct bilirubin must ≤ ULN, Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 ULN;\n3. Adequate renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL\u002Fmin;\n\nExclusion Criteria:\n\nPregnant or lactating women. History of any other malignancy. Patients in whom palliative radiotherapy is indicated in the opinion of the investigator.\n\nActive infection, congestive heart failure, myocardial infarction within the 6 months prior to enrollment, unstable angina pectoris or cardiac arrhythmia.\n\nPatients who have received tumor vaccine; or administration of live, attenuated vaccine within 4 weeks before the start of treatment.\n\nMental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.",{"count":142,"type":21},"This study is an observation, single center study to evaluate the alternations and prognostic value of peripheral blood lymphocyte (PBL) in patients diagnosed with thoracic cancers, including lung cancer, esophageal squamous cell carcinoma and thymic epithelial carcinoma underwent radiotherapy with or without chemotherapy.",[297,298,27],"NSCLC","Esophageal Squamous Cell Carcinoma","2020-08-19",{"date":301,"type":40},"2020-08-21",{"date":236,"type":40},{"date":304,"type":21},"2026-12",{"name":306,"class":75},"Shanghai Cancer Hospital, China"]